IGC Pharma Expands Alzheimer’s Trial as DataVault AI Grows Patent Portfolio

Apr 23, 2026

IGC Pharma (NYSE American: IGC) has added a new clinical site in Dallas to its Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer’s disease. With enrollment already around 80% complete, the addition of specialized behavioral neurology expertise is expected to support recruitment and strengthen clinical execution as the study advances.

In a separate update, DataVault AI announced the issuance of a new U.S. patent along with additional Notices of Allowance, expanding its intellectual property portfolio in data monetization and tokenization technologies. The milestone supports its strategy to accelerate commercialization and target $200 million in revenue for 2026.

#IGCPharma
#Alzheimers
#ClinicalTrials
#Biotech
#Neuroscience
#DataVaultAI
#Blockchain
#Tokenization
#Fintech
#Web3
#HealthcareInnovation
#MedicalResearch
#Innovation
#JaneKing
#NewsOut